SMART Medical Systems Ltd., a developer and manufacturer of innovative endoscopy products, today reported positive data from a multicenter clinical study (NCT 04708951) comparing the adenoma detection rate (ADR) of its FDA-cleared G-EYE® balloon technology against ENDOCUFF VISION® (ECV) technology in patients undergoing screening or surveillance colonoscopy. Results from this randomized trial, the first head-to-head comparison of these two colonoscopy mechanical enhancement devices, showed that the ADR, particularly for advanced and large adenomas, was higher for the G-EYE® balloon than for the ECV attachment. Seth Gross, MD, Professor, Department of Medicine at NYU Grossman School of Medicine, Clinical Chief, Division of Gastroenterology and Hepatology at NYU Langone Health, and co-author on the abstract, presented the data in an oral session at ACG 2021, which is taking place October 22-27 in Las Vegas (ACG 2021, Presidential Plenary Session 1, Abstract #S233).
Trending
- Long-term outcomes of top-down therapy versus a conventional step-up strategy in adults newly diagnosed with Crohn’s disease: 5-year follow-up of the PROFILE trial (The Lancet Gastroenterology & Hepatology)
- Low AST and ALT Levels Are Associated with Higher Likelihood of Early-Onset Colorectal Cancer in Adults Under 45 (Epic Research)
- Helicobacter pylori exposure linked to one in five cases of bowel cancer (News Medical)
- FDA Clears CU Anschutz Clinical Trial Using Engineered Immune Cells to Fight Colorectal Cancer (PR Newswire)
- A robot pill the size of a large vitamin swims through a stomach on 6 water jets while a doctor steers it with a game controller, and after $21 million it still cannot be used on a patient (The Pulse)
- GLP-1 users can have ‘terrific results’ with bariatric surgery to lose additional weight (Healio)
- GI faces another round of Medicare cuts under proposed 2027 rules (GI & Hepatology News)
- Fecal Occult Blood Screening Outcomes Adjusted for Contamination Bias and Nonadherence (JAMA Network)
